These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36299500)

  • 21. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy.
    Pascarella A; Terracciano C; Farina O; Lombardi L; Esposito T; Napolitano F; Franzese G; Panella G; Tuccillo F; la Marca G; Bernardini S; Boffo S; Giordano A; Di Iorio G; Melone MAB; Sampaolo S
    J Cell Physiol; 2018 Aug; 233(8):5829-5837. PubMed ID: 29215735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The frequency of late-onset Pompe disease in pediatric patients with limb-girdle muscle weakness and nonspecific hyperCKemia: A multicenter study.
    Ünver O; Hacıfazlıoğlu NE; Karatoprak E; Güneş AS; Sağer G; Kutlubay B; Sözen G; Saltık S; Yılmaz K; Kara B; Türkdoğan D
    Neuromuscul Disord; 2016 Nov; 26(11):796-800. PubMed ID: 27666774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective screening of late-onset Pompe disease (LOPD) in patients with non-diagnostic muscle biopsies.
    Meznaric M; Fumic K; Leonardis L
    J Clin Pathol; 2019 Jul; 72(7):468-472. PubMed ID: 30878973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case Report: Identification of Compound Heterozygous Mutations in a Patient With Late-Onset Glycogen Storage Disease Type II (Pompe Disease).
    Zhang H; Chen J; Zhu Y; Ma X; Zhong W
    Front Neurol; 2022; 13():839263. PubMed ID: 35386406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Late Onset Pompe Disease with Novel Mutations and Atypical Phenotypes.
    Chawla T; Preethish-Kumar V; Polavarapu K; Vengalil S; Bardhan M; Puri R; Verma J; Christopher R; Supriya M; Nashi S; Prasad C; Nadeesh B; Nalini A
    J Neuromuscul Dis; 2022; 9(2):261-273. PubMed ID: 34864681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic tools in late onset Pompe disease (LOPD).
    Musumeci O; Toscano A
    Ann Transl Med; 2019 Jul; 7(13):286. PubMed ID: 31392198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late-onset Pompe disease: what is the prevalence of limb-girdle muscular weakness presentation?
    Lorenzoni PJ; Kay CSK; Higashi NS; D'Almeida V; Werneck LC; Scola RH
    Arq Neuropsiquiatr; 2018 Apr; 76(4):247-251. PubMed ID: 29742245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
    Kroos MA; Pomponio RJ; Hagemans ML; Keulemans JL; Phipps M; DeRiso M; Palmer RE; Ausems MG; Van der Beek NA; Van Diggelen OP; Halley DJ; Van der Ploeg AT; Reuser AJ
    Neurology; 2007 Jan; 68(2):110-5. PubMed ID: 17210890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families.
    Napolitano F; Bruno G; Terracciano C; Franzese G; Palomba NP; Scotto di Carlo F; Signoriello E; De Blasiis P; Navarro S; Gialluisi A; Melone MAB; Sampaolo S; Esposito T
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [GAA gene variants and genotype-phenotype correlations in patients with glycogen storage disease type Ⅱ].
    Huang YL; Sheng HY; Jia XF; Su XY; Zhao XY; Xie T; Tang CF; Liu SC; Li XZ; Zhang W; Mei HF; Zeng CH; Liu L
    Zhonghua Er Ke Za Zhi; 2021 Mar; 59(3):189-194. PubMed ID: 33657692
    [No Abstract]   [Full Text] [Related]  

  • 31. Late-Onset Pompe Disease Presenting with Isolated Tongue Involvement.
    Al-Hashel J; Ismail I
    Case Rep Neurol; 2022; 14(1):98-103. PubMed ID: 35431876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing.
    Lévesque S; Auray-Blais C; Gravel E; Boutin M; Dempsey-Nunez L; Jacques PE; Chenier S; Larue S; Rioux MF; Al-Hertani W; Nadeau A; Mathieu J; Maranda B; Désilets V; Waters PJ; Keutzer J; Austin S; Kishnani P
    Orphanet J Rare Dis; 2016 Jan; 11():8. PubMed ID: 26809617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A genetic modifier of symptom onset in Pompe disease.
    Bergsma AJ; In 't Groen SLM; van den Dorpel JJA; van den Hout HJMP; van der Beek NAME; Schoser B; Toscano A; Musumeci O; Bembi B; Dardis A; Morrone A; Tummolo A; Pasquini E; van der Ploeg AT; Pijnappel WWMP
    EBioMedicine; 2019 May; 43():553-561. PubMed ID: 30922962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.
    Kishnani PS; Gibson JB; Gambello MJ; Hillman R; Stockton DW; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Day JW; Wang RY; Goldstein JL; An Haack K; Sparks SE; Zhao Y; Hahn SH;
    Genet Med; 2019 Nov; 21(11):2543-2551. PubMed ID: 31086307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease.
    Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA
    Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenotypic implications of pathogenic variant types in Pompe disease.
    Viamonte MA; Filipp SL; Zaidi Z; Gurka MJ; Byrne BJ; Kang PB
    J Hum Genet; 2021 Nov; 66(11):1089-1099. PubMed ID: 33972680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duchenne Muscular Dystrophy With Low Acidic α-Glucosidase Activity: Two Case Reports and Literature Review.
    He X; Li X; Lin Y; Ba H; Peng H; Zhang L; Zhu L; Qin Y; Li S
    Front Pediatr; 2022; 10():855510. PubMed ID: 35722482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.
    Vanherpe P; Fieuws S; D'Hondt A; Bleyenheuft C; Demaerel P; De Bleecker J; Van den Bergh P; Baets J; Remiche G; Verhoeven K; Delstanche S; Toussaint M; Buyse B; Van Damme P; Depuydt CE; Claeys KG
    Orphanet J Rare Dis; 2020 Apr; 15(1):83. PubMed ID: 32248831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The First Year Experience of Newborn Screening for Pompe Disease in California.
    Tang H; Feuchtbaum L; Sciortino S; Matteson J; Mathur D; Bishop T; Olney RS
    Int J Neonatal Screen; 2020 Mar; 6(1):9. PubMed ID: 33073007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interpretation of acid α-glucosidase activity in creatine kinase elevation: A case of Becker muscular dystrophy.
    Oitani Y; Ishiyama A; Kosuga M; Iwasawa K; Ogata A; Tanaka F; Takeshita E; Shimizu-Motohashi Y; Komaki H; Nishino I; Okuyama T; Sasaki M
    Brain Dev; 2018 Oct; 40(9):837-840. PubMed ID: 29778277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.